Zacks Research Has Bullish Outlook for Omnicell Q1 Earnings

Omnicell, Inc. (NASDAQ:OMCL) – Stock analysts at Zacks Research lifted their Q1 2025 earnings per share (EPS) estimates for shares of Omnicell in a research note issued to investors on Tuesday, January 28th. Zacks Research analyst R. Department now anticipates that the company will earn $0.17 per share for the quarter, up from their prior estimate of $0.16. The consensus estimate for Omnicell’s current full-year earnings is $0.94 per share. Zacks Research also issued estimates for Omnicell’s Q3 2025 earnings at $0.18 EPS, FY2025 earnings at $0.86 EPS and Q1 2026 earnings at $0.27 EPS.

Several other analysts also recently weighed in on OMCL. Bank of America reduced their price objective on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. StockNews.com downgraded shares of Omnicell from a “buy” rating to a “hold” rating in a research note on Tuesday, December 10th. Craig Hallum lifted their target price on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Wells Fargo & Company reduced their target price on Omnicell from $49.00 to $40.00 and set an “equal weight” rating for the company in a report on Monday, January 13th. Finally, JPMorgan Chase & Co. raised their price target on Omnicell from $37.00 to $44.00 and gave the stock a “neutral” rating in a research note on Thursday, November 21st. Five equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, Omnicell currently has an average rating of “Hold” and a consensus price target of $50.00.

Omnicell Stock Down 0.4 %

Shares of OMCL opened at $44.69 on Thursday. Omnicell has a 52-week low of $25.12 and a 52-week high of $55.74. The stock has a 50 day moving average price of $44.62 and a 200 day moving average price of $42.62.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. Van ECK Associates Corp boosted its position in shares of Omnicell by 47.0% during the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after purchasing an additional 315 shares in the last quarter. GAMMA Investing LLC boosted its holdings in Omnicell by 78.4% during the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after buying an additional 553 shares in the last quarter. KBC Group NV grew its position in Omnicell by 60.8% during the fourth quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after buying an additional 778 shares during the period. 1620 Investment Advisors Inc. increased its holdings in Omnicell by 230.1% in the third quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after buying an additional 1,542 shares in the last quarter. Finally, Summit Global Investments acquired a new stake in shares of Omnicell during the 3rd quarter valued at approximately $221,000. 97.70% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Omnicell

In other Omnicell news, Director Mark W. Parrish sold 12,000 shares of the company’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the completion of the transaction, the director now owns 58,427 shares in the company, valued at approximately $2,763,597.10. This represents a 17.04 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 2.64% of the stock is owned by company insiders.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.